GlassScriptPhysician profile
Elizabeth G Grattan
NPI 1477641801
$3,636.21
in general payments reported to CMS, 2019-2025
33 companies · $953 in 2025
The $953 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $55.78 · 2021: $69.46 · 2022: $587 · 2023: $537 · 2024: $864 · 2025: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,354.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $590.44 | 2019-2025 | |
| Pfizer INC. | $451.13 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $313.25 | 2019-2025 | |
| Janssen Biotech, INC. | $276.65 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $237.35 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $218.05 | 2019-2025 | |
| Incyte Corporation | $167.57 | 2022-2025 | Opzelura |
| Ucb, INC. | $165.57 | 2019-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $132.89 | 2023-2025 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $110.57 | 2019-2024 | Cabtreo, Jublia |
| Dermavant Sciences, INC. | $95.61 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $92.06 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $89.20 | 2019-2023 | Taltz, Olumiant |
| Novartis Pharmaceuticals Corporation | $82.98 | 2019-2023 | |
| Almirall LLC | $79.36 | 2019-2025 | Klisyri |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $72.05 | 2024 | |
| Leo Pharma INC. | $70.34 | 2022-2024 | Adbry |
| Amgen INC. | $46.53 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $45.73 | 2023-2024 | Idacio |
| Sandoz INC. | $44.50 | 2019-2025 | Hyrimoz |
| Celgene Corporation | $38.42 | 2019 | |
| Allergan, INC. | $37.76 | 2022 | |
| Journey Medical Corporation | $29.01 | 2022 | |
| Botanix Sb INC | $20.88 | 2025 | Sofdra |
| Dermira, INC. | $19.70 | 2019 | |
| Aclaris Therapeutics, INC. | $18.85 | 2019 | |
| Vyne Pharmaceuticals INC. | $18.39 | 2021 | |
| Epi Health, LLC | $17.12 | 2019 | |
| Verrica Pharmaceuticals INC. | $16.29 | 2023 | Ycanth |
| Novum Pharma, LLC | $14.73 | 2019 | |
| Galderma Laboratories, L.P. | $14.17 | 2024 | |
| Organon LLC | $5.59 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $3.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Grattan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.